Company / R&D Expense
NewAmsterdam Pharma Co N.V. R&D Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$141.8M
FY2025
5-year range
$29.0M / $159.4M
FY2021-FY2025
Trend
-6.3%
vs FY2024
Sector context
#107 of 208
Health Care
What the data says
At $142M, NewAmsterdam Pharma Co N.V.'s r&d expense ranks #107 of 208 in the Health Care sector. Declined from $159M to $142M over the past 2 years.
Based on SEC 10-K filings.
$142M in FY2025 with a 3-year CAGR of +17.8%.
Declined from $159M to $142M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +17.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#107 of 208 in Health CareTop 51% of 208This company $141.8M Sector average $644.3M
▼
-78.0% below sector average
Key checks
Key Insights
- 3-year CAGR of +17.8%, indicating consistent growth.
- In FY2025, r&d expense decreased 6.3% year-over-year.
- Ranks #107 out of 208 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $141.8M | -6.3% |
| FY2024 | $151.4M | -5.0% |
| FY2023 | $159.4M | +83.8% |
| FY2022 | $86.7M | +199.4% |
| FY2021 | $29.0M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026